Sitala
Overview
Stop Harmful Inflammation and Get Better. Treating Neurodegenerative and Inflammatory Diseases.
Funding and backers
Latest round
Venture round
Mar 2026 · 7 mo ago
Backers
1
OrbiMed
The money's age
Fresh money
7 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 19
Raised a round Venture round
Sep 9, 2025
Raised a round Venture round
Nov 17, 2022
Raised a round Venture round
Dec 15, 2021
Raised a round Venture round
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Mar 2026 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | Sep 2025 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | Nov 2022 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | Dec 2021 | — | — | find-and-update.company-information.service.gov.uk |
Registers and programsofficial lists and records that name the company
| Legal entity | 751256 Sitala Bio Ltd | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
We believe that clinical remission should be the standard—not the exception—for treating chronic inflammatory diseases like COPD, asthma…
At QuantX, we leverage the power of computation and modeling to accelerate the discovery of superior medicines for validated targets in…
Our modular engineering platform allows us to create optimized Tregs phenotypes tailored to address a wide variety of autoimmune…
Our Mission. Deliver medicines that transform the lives of patients with neurodegenerative diseases.
A biotech company developing better medicines for patients with autoimmune and inflammatory diseases. Leveraging powerful insights into the…
Gesynta Pharma is a Swedish pharmaceutical company that develops unique drug candidates with the aim to reduce harmful inflammation and…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Report
Controversial K-pop idol Sitala leaves girl group H1-KEY only five months after debut
Sitala, a member of rookie girl group H1-KEY, has parted ways with the K-pop act only five months after their debut.
Read more
Report
Sitala出道四個月退出H1-KEY 曾因父親陷爭議
2022年1月5日才以單曲ATHLETIC GIRL出道的韓國女團H1-KEY出道至今不到五個月泰國成員Sitala就因個人因素退出團體
Read more
Report
Report
H1-KEY所屬社表明「不會換成員」反SITALA泰國網友持續抵制：「她就是軍政府的擁護者」
即將出道的女團H1-KEY泰籍成員SITALA遭泰國網友抵制目前所屬社發表聲明不會換成員反對SITALA的網友持續反對甚至挖出更多證據證明她親自參與過政治
Read more
Report
H1-KEY所属社表明「不会换成员」反SITALA泰国网友持续抵制：「她就是军政府的拥护者」
即将出道的女团H1-KEY泰籍成员SITALA遭泰国网友抵制目前所属社发表声明不会换成员反对SITALA的网友持续反对甚至挖出更多证据证明她亲自参与过政治
Read more
Report
H1-KEY's agency says Thai member Sitala will remain in the group despite backlash
Grandline Group has announced that Sitala will remain part of upcoming girl group H1-KEY, in spite of the ongoing controversy.
Read more
Report